Work

PD-1/PD-L1 blockade in renal cell cancer

Year: 2016

Type: review

Abstract: INTRODUCTION: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

Source: Expert Review of Clinical Immunology

DOI: 10.1080/1744666x.2016.1214575

Authors: Kathryn E. Beckermann, Douglas B. Johnson, Jeffrey A. Sosman

Institutions: Vanderbilt University Medical Center, Northwestern University, Northwestern Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute